EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieMultizentrische StudieVergleichsstudieOpen Access · CC BY 4.0

Effects of valsartan vs amlodipine and achieved lower blood pressure on the incidence of end-stage kidney disease: The VALUE Trial

Eirik Olsen, Kenneth Jamerson, Roland E Schmieder, Camilla L Søraas, Julian E Mariampillai, Giuseppe Mancia, Sverre E Kjeldsen, Sondre Heimark, Maria H Mehlum, Knut Liestøl, Anne C K Larstorp, Lene V Halvorsen und 5 weitere

European Journal of Internal Medicine · 2025-03 · 133 · 55-63

DOI: 10.1016/j.ejim.2024.12.021 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift European Journal of Internal Medicine, 2025-03. Verfasst von Eirik Olsen und 16 weiteren Autor:innen. Beteiligte Einrichtung: The Norwegian University of Science and Technology, Trondheim, Norway; St. Olav´s University Hospital, Trondheim, Norway. Hauptthemen laut MEDLINE: Valsartan, Amlodipine, Kidney Failure, Chronic, Antihypertensive Agents. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 49 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Novartis Pharma, Novartis Pharmaceuticals Corporation, Research Council of Norway.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: There is a paucity of data investigating the impact of antihypertensive drug classes and blood pressure (BP) treatment targets on the incidence of end-stage kidney disease (ESKD). In patients with high-risk hypertension aged 50-80 years or above, we aimed to, 1) compare effects of valsartan, an angiotensin receptor blocker, with amlodipine, a calcium channel blocker and, 2) assess the effect of achieving systolic BP

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ValsartanAmlodipineKidney Failure, ChronicAntihypertensive AgentsHypertensionCalcium Channel BlockersHumansMaleFemaleAgedMiddle AgedDouble-Blind MethodBlood PressureProspective StudiesIncidenceAged, 80 and overProportional Hazards Models

Stichwörter der Autor:innen

AmlodipineBlood pressureCardiovascular diseaseHypertensionKidney failureValsartan

Substanzen

ValsartanAmlodipineAntihypertensive AgentsCalcium Channel Blockers

Autor:innen und Institutionen

  • The Norwegian University of Science and Technology, Trondheim, Norway; St. Olav´s University Hospital, Trondheim, Norway.
  • University of Michigan, Ann Arbor, MI, USA.
  • University of Erlangen, Erlangen, Germany.
  • Oslo University Hospital, Ullevaal, Oslo, Norway; University of Oslo, Oslo, Norway.
  • Akershus University Hospital, Lørenskog, Norway.
  • University of Milan-Bicocca, Milan, Italy.

Förderung

  • Novartis Pharma
  • Novartis Pharmaceuticals Corporation
  • Research Council of Norway

Zitieren

APA

Olsen, E., Jamerson, K., Schmieder, R. E., Søraas, C. L., Mariampillai, J. E., Mancia, G., Kjeldsen, S. E., Heimark, S., Mehlum, M. H., Liestøl, K., Larstorp, A. C. K., Halvorsen, L. V., Høieggen, A., Burnier, M., Rostrup, M., Julius, S., & Weber, M. A. (2025). Effects of valsartan vs amlodipine and achieved lower blood pressure on the incidence of end-stage kidney disease: The VALUE Trial. European Journal of Internal Medicine, 133, 55-63. https://doi.org/10.1016/j.ejim.2024.12.021

Vancouver

Olsen E, Jamerson K, Schmieder RE, Søraas CL, Mariampillai JE, Mancia G, et al. Effects of valsartan vs amlodipine and achieved lower blood pressure on the incidence of end-stage kidney disease: The VALUE Trial. European Journal of Internal Medicine. 2025;133:55-63. doi:10.1016/j.ejim.2024.12.021

BibTeX
@article{Olsen2025,
  author = {Olsen, Eirik and Jamerson, Kenneth and Schmieder, Roland E and Søraas, Camilla L and Mariampillai, Julian E and Mancia, Giuseppe and Kjeldsen, Sverre E and Heimark, Sondre and Mehlum, Maria H and Liestøl, Knut and Larstorp, Anne C K and Halvorsen, Lene V and Høieggen, Aud and Burnier, Michel and Rostrup, Morten and Julius, Stevo and Weber, Michael A},
  title = {Effects of valsartan vs amlodipine and achieved lower blood pressure on the incidence of end-stage kidney disease: The VALUE Trial},
  journal = {European Journal of Internal Medicine},
  year = {2025},
  volume = {133},
  pages = {55--63},
  doi = {10.1016/j.ejim.2024.12.021}
}
Kostenlos starten →